In biotechnology, where hypotheses can shift as quickly as new data emerges, one of the most difficult calls a scientific leader must make is knowing when to keep pushing an idea and when new evidence should change the direction. That challenge sits at the center of a perspective offered by Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer at BE Therapeutics, who has spent more than three decades moving between academic research, biotech entrepreneurship, and R&D leadership.
Ashton-Rickardt’s career has included professorships at the University of Chicago and Imperial College London, founding Smith Therapeutics, serving as Chief Scientific Officer at Sigilon Therapeutics, advising companies through Flagship Pioneering, and helping build Halyard Therapeutics and BE Therapeutics. Across those settings, he has seen how easily commitment to an idea can become attachment to it. “You have to separate attachment to the idea from attachment to the problem,” Ashton-Rickardt said. “If the problem is important, there may be several ways to approach it.”
That distinction matters because biotech programs rarely unfold in a straight line. A hypothesis that looked promising at the start of a project may need to be adjusted, narrowed, or abandoned entirely. For Ashton-Rickardt, changing direction does not automatically mean an earlier idea failed. In many cases, it can mean the team has learned enough to make a better decision. “Flexibility is important because changing your approach is not necessarily an admission that you failed,” he said. “Sometimes it is evidence that you learned something.”
His views carry weight at a time when drug developers face pressure to deliver results under uncertainty. One of the more difficult parts of scientific leadership, he believes, is providing direction without creating false certainty. Researchers, executives, investors, and teams often need decisions before every question has been answered, which creates pressure on leaders to sound more certain than the evidence may justify. Ashton-Rickardt sees a better approach in being clear about what is known, what remains uncertain, and what would cause a decision to change. “There is a difference between providing direction and pretending to know the future,” he said. “In biotech, there are simply too many unknowns.”
Rather than weakening confidence, that kind of transparency can strengthen it. When teams understand that new information is expected to influence decisions, they may be more willing to raise concerns, question assumptions, and share evidence that challenges the current plan. That has implications not only for how experiments are run but for how companies decide where to invest time and resources.
Ashton-Rickardt’s perspective has been shaped by a career that repeatedly required him to enter unfamiliar territory. Raised in a working-class family in the UK, he worked his way through university and into academic science before eventually leaving a long-established academic career to return to Boston and start a biotech company. That transition required him to learn a new operating environment while still drawing on years of scientific experience. He has since moved between startups, established biotech companies, research organisations, and investment-backed environments. Throughout those changes, he says curiosity has remained one of the most important qualities a leader can keep. “The people I enjoy working with tend to ask good questions, even when those questions make the project more complicated,” Ashton-Rickardt said.
He also believes leaders should be willing to admit what they do not know. In his experience, someone who has thought deeply about an idea does not need to pretend it has no weaknesses. Instead, strong scientific thinking often shows up in the ability to explain what evidence would change a person’s mind. That mindset can make scientific organisations more adaptable at a time when new tools, new data, and new therapeutic approaches continue to change what is possible.
Ashton-Rickardt’s current work remains focused on engineered cell therapies and approaches to treating neurological and other serious diseases. At BE Therapeutics, where he serves as Managing Director and Chief Scientific Officer, and at Halyard Therapeutics, where he is a co-founder and Chief Scientific Officer, his work continues to centre on translating complex scientific ideas into programmes that can move forward. That process, he says, requires conviction, but conviction has to remain connected to evidence. “The goal is not to prove that your first idea was right,” Ashton-Rickardt said. “The goal is to solve an important problem.”
